The influence of typical and atypical neuroleptic drugs in the production of interleukin-2 and interferon-gamma in vitro

Neuropsychobiology

Volumn 46, Issue 4, 2002, Pages 180-185

  Rudolf, Sebastian ^a   Peters, Marion ^b   Rothermundt, Matthias ^b   Arolt, Volkert ^b   Kirchner, Holger ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Antidepressant medication; Cytokines; Interferon gamma; Interleukin 2; Neuroleptic medication; Schizophrenia

Indexed keywords

AMITRIPTYLINE; CLOZAPINE; GAMMA INTERFERON; HALOPERIDOL; INTERLEUKIN 2; NEUROLEPTIC AGENT; PHYTOHEMAGGLUTININ;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; INTERFERON PRODUCTION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; HALOPERIDOL; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; SCHIZOPHRENIA;

EID: 0036974867     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067807     Document Type: Article

References (25)

1. Villemain F, Chatenoud L, Guillibert E, et al: Decreased production of interleukin-2 in schizophrenia. Ann NY Acad Sci 1987;469:669-675.
2. Ganguli R, Rabin BS, Belle SH: Decreased interleukin-2 production in schizophrenic patients. Biol Psychiatr 1989;26:427-430.
3. Wilke I, Arolt V, Rothermundt M, et al: Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1996;246:279-284.
4. Moises HW, Schindler L, Leroux M, et al: Decreased production of interferon alpha and interferon gamma in leukocyte cultures of schizophrenic patients. Acta Psychiatr Scand 1985;72:45-50.
5. Rothermundt M, Arolt V, Weitzsch C, et al: Decreased production of IFN-gamma in acute schizophrenia. Biol Psychiatry 1996;40:1294-1297.
6. Arolt V, Weitzsch C, Wilke I, et al: Production of IFN-γ in families with multiple occurrence of schizophrenia. Psychiatr Res 1997;66:145-151.
7. Arolt V, Rothermundt M, Wandinger KP, et al: Decreases in in-vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiat 2000;5:150-158.
8. Rapaport MH, Lohr JB: Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr Scand 1994;90:311-315.
9. Mueller N, Empl M, Riedel M, et al: Neuroleptic treatment increases soluble IL-2 receptors and IL-6 receptors in schizophrenia. Eur Arch Psychiatr Clin N 1997;247:308-313.
10. Catheley GB, Amor B, Fournier C: Defective IL-2 production in active rheumatoid arthritis: Regulation by radiosensitive suppressor cells. Clin Rheumatol 1986;5:482-492.
11. Wandinger KP, Wessel K, Neustock P, et al: Diminished production of type I interferon and IL-2 in patients with multiple sclerosis. J Neurol Sci 1997;149:87-93.
12. Maes M, Bosmans E, Kenis G, et al: In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 1997;26:221-225.
13. McAllister CG, van Kammen DP, Rehn TJ, et al: Increases in CSF levels of interleukin-2 in schizophrenia: Effects of recurrence of psychosis and medication status. Am J Psychiatry 1995;152:1291-1297.
14. Haack M, Hinze-Selch D, Fenzel T, et al: Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis. J Psychiatry Res 1999;33:407-418.
15. Hornberg M, Arolt V, Wilke I, et al: Lymphokine production in leukocyte cultures of patients with schizophrenia. Schizophr Res 1995: 15:237-242.
16. Rothermundt M, Arolt V, Leadbeater J, et al: Cytokine production in unmedicated and treated schizophrenic patients. Neuroreport 2000;11:3385-3388.
17. Kirchner H, Kleincke C, Diegel W, et al: A whole blood technique for testing production of interferon by leukocytes. Immunol Meth 1982;48:213-219.
18. Ganguli R, Rabin ES: Increased serum interleukin-2 receptors in schizophrenic and brain damaged patients. Arch Gen Psychiatr 1989;46:292.
19. Bessler H, Levental Z, Karp L, et al: Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol Psychiatry 1995;38:297-302.
20. Ganguli R, Brar JS, Chengappa KR, et al: Mitogen stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients: The influence of age at onset and negative symptoms. Arch Gen Psychiatry 1995;52:668-672.
21. Altamura AC, Boin F, Maes M: HPA axis and cytokines dysregulation in schizophrenia: Potential implications for the antipsychotic treatment. Eur Neuropsychopharmacol 1999;10:1-4.
22. Pollmächer T, Hinze-Selch D, Fenzel T, et al: Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Am J Psychiatr 1997;154:1763-1765.
23. Hinze-Selch D, Becker EW, Stein GM, et al: Effects of clozapine on in vitro immune parameters: A longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology 1998;19:114-122.
24. Song C, Lin A, Kenis G, et al: Immunosuppressive effects of clozapine and haloperidol: Enhanced production of the interleukin-1 receptor antagonist. Schizophr Res 2000;42:157-164.
25. Moots RJ, Al-Saffar Z, Hutchinson D: Old drug, new trick: Haloperidol inhibits secretion of proinflammatory cytokines. Ann Rheum Dis 1999;58:585-587.